BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 10-Oct-2021

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 21, 2021 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.

SQURPHARMA 12-May-2021

In response to a DSE query dated May 09, 2021 regarding clarification on recent news published in the newspaper on launching factory in Kenya, the Company has informed that "It is a 100% subsidiary of Square Pharmaceuticals Limited, Bangladesh and the construction of the pharmaceuticals manufacturing facility in Nairobi, Kenya is at finishing stage. It shall go for commercial production subject to completion of Kenyan regulatory compliance process by August 2021."

SQURPHARMA 06-May-2021

(Continuation news of SQURPHARMA): and Consolidated NOCFPS: Consolidated NAV per share is increased due to incremental Net Profit in comparing to the reporting period ended on March 31, 2020. Consolidated EPS increased due to positive revenue. Consolidated NOCFPS decreased due to higher investment on working capital and higher advance tax payment to facilitate revenue growth in comparing to the same reporting period of previous year. (end)

SQURPHARMA 06-May-2021

(Q3 Un-audited): Consolidated EPS was Tk. 4.36 for January-March 2021 as against Tk. 4.08 for January-March 2020; Consolidated EPS was Tk. 13.12 for July 2020-March 2021 as against Tk. 11.85 for July 2019-March 2020. Consolidated NOCFPS was Tk. 9.40 for July 2020-March 2021 as against Tk. 9.64 for July 2019-March 2020. Consolidated NAV per share was Tk. 96.43 as on March 31, 2021 and Tk. 87.28 as on June 30, 2020. Reason for Significant deviation in Consolidated NAV per share, Consolidated EPS (cont.)

SQURPHARMA 02-May-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on May 06, 2021 at 1:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2021.

SQURPHARMA 31-Jan-2021

(Q2 Un-audited): The Company has further informed that Consolidated EPS was Tk. 4.33 instead of 4.18 for October-December 2020 as against Tk. 3.98 instead of Tk. 3.70 for October-December 2019. All other information will remain unchanged.

SQURPHARMA 31-Jan-2021

(Q2 Un-audited): Consolidated EPS was Tk. 4.18 for October-December 2020 as against Tk. 3.70 for October-December 2019; Consolidated EPS was Tk. 8.76 for July-December 2020 as against Tk. 7.77 for July-December 2019. Consolidated NOCFPS was Tk. 7.28 for July-December 2020 as against Tk. 5.60 for July-December 2019. Consolidated NAV per share was Tk. 92.47 as on December 31, 2020 and Tk. 87.28 as on June 30, 2020.

SQURPHARMA 24-Jan-2021

The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2020 to the respective shareholders.

SQURPHARMA 24-Jan-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 28, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.

SQURPHARMA 24-Dec-2020

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2020; unaudited financials up to September 30, 2020 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

Previous Next page